Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Ascension Health Ventures leads Ivantis' $27mm Series B venture round; adds money to close at $71.5mm

Executive Summary

Ascension Health Ventures has led Ivantis Inc.’s (treatments for eye diseases, including glaucoma) $27mm Series B venture round. Fellow returning backers New Enterprise Associates and Delphi Ventures participated and were joined by new investors MemorialCare Innovation Fund. Ivantis will use the money for four multi-center clinical trials to study its Hydrus microstent versus GlaukosiStent trabecular microbypass technology used in micro-invasive glaucoma surgery.
Deal Industry
  • Medical Devices
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies